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Background: Domestic violence and abuse is threatening behavior, violence/abuse used by one person to control the
other within an intimate or family-type relationship. Women experience more severe physical and sexual domestic
violence and abuse and more mental health consequences than men. The current study aims at exploring of the role
of hypothalamic-pituitary-adrenocortical axis activity in abuse impact on women's mental health. Study objectives:
1) To evaluate diurnal cortisol slope, cortisol awakening response, and the mean cortisol concentration in women with
a current or recent experience of abuse; 2) To estimate whether cortisol secretion is associated with type, severity,
duration and cessation of abuse; 3) To investigate whether cortisol acts as mediator between abuse and mental health
condition; 4) To examine whether there is any distinction in cortisol levels between those women exposed to both
childhood abuse and domestic violence and abuse and those experienced only the latter. 4) To explore whether
cortisol secretion differs between women living in refuge and those still living in the community.
Methods/Design: To meet study objectives 128 women will be recruited in a domestic violence agency and local
communities. Baseline and 3-month follow-up measures will be taken over 6 months after recruitment. Each assessment
will include: (1) standardized self-administered questionnaires to evaluate socio-demographics, experience of violence and
abuse, mental and physical health; (2) weight and height measurement; (3) self-completion of wakening, post-wakening
and evening saliva samples. Saliva will be analysed for cortisol and cortisone using Ultra performance liquid
chromatography – tandem mass spectrometry.
We will compare diurnal cortisol parameters between non-abused controls and abuse survivors with and without mental
health conditions. First following descriptive statistics for all the cortisol and mental health outcomes, relationships
between them will be investigated using appropriate regression models. Second, these techniques will be used to
investigate the extent to which cortisol measures act as potential mediators between type, severity, duration of abuse
and mental disorders.
Discussion: Results of the study will increase our understanding of the pathophysiological mechanisms of abuse-related
mental health disorders in women and inform researchers and practitioners on the possibility of using salivary cortisol as
a biological marker for prognosis, diagnosis, and treatment evaluation among abuse survivors.
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Domestic violence and abuse (DVA) is threatening be-
havior, violence or abuse (psychological, physical, sexual,
financial or emotional) between adults who are or have
been intimate partners or family members, regardless of
gender and sexuality. DVA can be better understood as a
chronic syndrome characterized not only by episodes of
physical violence but also by the emotional and psycho-
logical abuse the perpetrators use to maintain control
over their partners [1]. Life time prevalence of DVA is
28% for women and 18% for men, although severity and
consequences of abuse are less for men [2]. Over and above
damage to physical and reproductive health DVA has long-
term detrimental effects on mental health for women con-
sulting in primary care [3,4]. High prevalence of lifetime
and past year DVA is reported in psychiatric female pa-
tients [5]. A meta-analysis of (mostly) North American
studies measuring the relationship between DVA and men-
tal disorders reported increased risk for depression, anxiety,
psychosomatic disorders, posttraumatic stress disorder
(PTSD), alcohol abuse, and suicidal behavior [6]. Compared
to non-abused women, female victims of DVA visit their
general practitioners more frequently. They are also more
often referred to additional diagnostics and mental health
care, as well as prescribed antidepressants [7]. Kernic et al.
[8] have established that cessation of DVA among survivors
is associated with decreased prevalence of depression;
whereas Anderson and Sounders [9] have found that some
women out of the abusive relationship may have greater
psychological difficulties than those who are still in it.
Blasco et al. [10] concluded that the pattern of mental
health recovery depends on the type of DVA that the
women had been exposed to.
In addition, the mechanisms through which DVA causes
mental and physical conditions are very poorly studied.
One mechanism that may contribute to stress-related dis-
orders is the hypothalamic-pituitary-adrenocortical (HPA)
axis, which produces cortisol [11-13]. Cortisol activity in
healthy children and adults follows a consistent diurnal
pattern with peak levels of output observed within the first
30–40 min after awakening followed by a progressive re-
duction throughout the morning and afternoon with a
nadir around midnight [14]. Cortisol levels naturally in-
crease in response to exposure to acute stress and helps
organisms cope with a short term homeostatic challenges
by modification of metabolic and cognitive function [15].
Chronic stress has the capacity to increase or decrease
HPA activity, and the resulting pattern depends, both on
features of the stressor and the person facing it. Female
survivors describe DVA as traumatic uncontrollable stress
that poses a threat to their physical and social self, and is
associated with feelings of shame [16]. There are very few
studies focused on assessing physiologic correlates of
chronic stress in abused women.Salivary cortisol has been successfully used as a bio-
logical marker of HPA axis activity in epidemiological
studies [17,18] including samples of women exposed to
DVA [19-21]. Diurnal cortisol slope, cortisol awakening
response (CAR), and area under the daytime cortisol curve
have been found the most robustly related to psychosocial
phenomena and to health outcomes [22]. Systematic re-
view of the endocrine sequelae in chronically stressed but
non psychiatric caregivers for family members reveals four
studies which reported no difference, five studies reporting
increased cortisol output, and four studies reporting hypo-
secretion of cortisol compared to controls [23]. Powell
et al. [20] have found out that women chronically stressed
by undergoing a divorce or separation displayed elevated
evening salivary cortisol compared to no stressed women
in stable marriages. Moreover, it was the chronic stress ra-
ther than depression or acute stress that accounted for the
elevation of evening salivary cortisol. Systematic review
and meta-analysis of cortisol and posttraumatic stress dis-
order revealed significantly lower cortisol levels in people
with PTSD due to sexual or physical abuse than controls.
Interestingly, no difference in cortisol levels was found be-
tween controls and people with PTSD due to other types of
trauma [24]. In contrast, anxiety disorder was associated
with higher awakening cortisol levels [25]. Meta-analysis of
studies meeting methodological standards showed that de-
pression was associated with small-to-moderate elevation
in cortisol output [26].
Long-term studies are absent in the field of patho-
physiology of DVA [22]. The results of existing cross-
sectional and short-term longitudinal studies testing the
impact of childhood abuse and DVA on women’s HPA
axis functioning are contradictory (see Additional file 1).
It is evident that most investigators have reported dif-
ferent patterns of alterations in diurnal cortisol output
in women exposed to childhood abuse (CHA) and DVA.
However there are researchers who have concluded that
cortisol is a marker of abuse exposure rather than men-
tal health diagnosis [27,28]; others stated that alteration
in cortisol output is a correlate of abuse-related mental
disorder [29,30]. Currently, it is known that CHA influ-
ences the psychobiology of cortisol function and that there
is a development from hyper secretion of cortisol to hypo
secretion by early adulthood [14]. It is also known that
both physical and psychological DVA have significant im-
pacts on the neuroendocrine system of women [27]. At
the same time it is not clear whether currently and re-
cently abused women, who have abnormal diurnal cortisol
profiles, demonstrate poorer mental health outcomes and
how this may correlate with type, severity, duration and
cessation of abuse. There is a hypothesis that DVA survi-
vors may be characterized by alterations in HPA axis activ-
ity [31] and that further longitudinal studies are needed to
identify specific stress system disturbances in this group
Lokhmatkina et al. BMC Psychiatry 2013, 13:188 Page 3 of 8
http://www.biomedcentral.com/1471-244X/13/188[2,32]. The current research study aims to investigate the
role of the HPA axis on the impact of DVA on women’s
mental health. This study tests the hypothesis that com-
pared to non-abused controls all abused women have al-
tered diurnal rhythm in cortisol secretion and that the
pattern of this alteration is predicted by abuse characteris-
tics, such as its type, severity, duration, and cessation.
Study objectives
1. To evaluate the key diurnal cortisol parameters
(diurnal cortisol variation, CAR, and mean cortisol
concentration) in women with a current or recent
experience of DVA
2. To estimate whether cortisol parameters are
associated with type, severity, duration and cessation
of abuse
3. To investigate whether cortisol outcomes act as a
mediator between the features of abuse and mental
health state
4. To examine whether there is any distinction in
cortisol levels between those women exposed to both
CHA and DVA and those experienced only the latter
5. To explore whether cortisol secretion differs
between women, living in a domestic violence refuge
and those still living in the community
(after adjustment for confounding effects of abuse
severity and continuing contact with abuser).
Methods/Design
The study was approved by a Research Ethics Committee
established by the NHS Health Research Authority (NRES
Committee South West – Frenchay, REC reference 12/
SW/0162 of 25 June 2012). This is a 6-month, prospective,
observational study based on a convenience sample. We
will recruit index participants from the pool of women re-
ferred to specialized domestic violence agency SURVIVE
South Gloucestershire and Bristol for community out-
reach support or refuge accommodation by other agen-
cies or self-referred. The SURVIVE agency is a charitable
organization which provides a range of services to
women who have experienced DVA, including three
refuges for women with children, outreach support,
community-based Freedom Program groups, Independ-
ent Domestic Violence Advisers, support phone line,
and Information Sessions in South Gloucestershire, and
Bristol UK.
Inclusion criteria for participants contain age ≥ 18 y.o.
Exclusion criteria include inability to read English,
current use of steroid-based medications, pregnancy,
presence of pituitary and/or adrenal gland disorder, and
symptomatic psychotic illness. No participant will be
excluded on the basis of their disability, ethnicity, reli-
gion or sexual orientation.Recruitment
Potential index participants will be identified by written
invitation letters with invitation slip attached offered by
researcher or agency staff to every woman referred or
self-referred to domestic violence agency SURVIVE.
Woman willing to be approached to discuss potential
participation in the study can either send her contact
details to the researcher by phone or e-mail, or put
down her contact details on the invitation slip, tear it
off and return to the researcher or agency staff who has
given the invitation to her.
The researcher will collect contact details sent by phone,
e-mail, and completed invitation slips and phone all
women willing to be approach to hear more about the
study. When initial telephone contact has been made with
a woman, the researcher will assess her eligibility and ar-
range a face-to-face meeting with all women interested and
eligible to take part, meeting the woman at a safe and con-
venient place. As part of the first face-to-face meeting, the
researcher will give a detailed participant information sheet
to the woman, explaining each point and answer any ques-
tions that the woman may have prior to seeking her writ-
ten informed consent.
The researcher will ask every woman already consented
to participate in the study to suggest up to three female
friends or family members of the same age group who are
aware of her current circumstances to be her potential
controls. The researcher will emphasize that suggesting
friend controls is completely optional. If a woman does
not want to recommend friend controls it will not affect
her participation in the study nor the services she receives.
If a woman wishes to suggest friends as potential controls
the researcher will ask her to pass ‘An invitation to the
CEASE study’ to those people. ‘An invitation to the
CEASE study’ and all documentation for friend controls
present the study as biological research on the impact of
family stress on women's health and wellbeing and do not
mention SURVIVE agency. Although it does state that the
research is about DVA, the researcher will ask the index
participant only to pass the invitation to confidantes who
know that she has experienced abuse. A friend control
willing to discuss potential participation in the study will
send her contact details to the researcher by post, phone,
text, or e-mail. The researcher will contact potential friend
controls by phone to give brief information about the
study, assess their eligibility and arrange a face-to-face
meeting at a safe and convenient place. As part of the first
face-to-face meeting, the researcher will give a detailed par-
ticipant information sheet to the friend control, explaining
each point and answer any questions that the woman may
have prior to seeking her written informed consent. In par-
allel with recruitment of friend controls through index re-
search participants we will approach potential controls in
local communities through invitation letters displayed in
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munity centre) in areas surrounding SURVIVE sites in
South Gloucestershire and Bristol.
Measurements
This study will consist of one baseline and two follow-
up measurements. Baseline evaluation will be carried
out at the first face-to-face meeting between researcher
and woman and during the following week. Women will
be asked to undertake follow-up assessment at 3 and 6
months after joining the study. With regard to safety
preferences participants will have a choice to receive and
return follow-up questionnaire and saliva collection kit
by post or at the follow-up face-to-face meeting with the
researcher. Each assessment will last approximately 45
minutes and will include: (1) numerous standardized self-
administered questionnaires to assess socio-demographics,
mental and physical health, (2) weight and height meas-
urement, and (3) self-completion of three saliva samples.
The questionnaire and saliva samples will be completed
by the participant at a place that is safe and convenient to
her and returned by post or via collection by the re-
searcher. Research plan and measurements are summa-
rized in Additional file 2.
Socio-demographic information will be collected through
use of a standardized self-report questionnaire and include
age, ethnicity, children, qualifications, employment sta-
tus, total annual income and relationship to perpetrator.
Exposure to abuse through the lifespan will be measured
using two psychological instruments. First, cases of child-
hood abuse and neglect will be detected using the Child-
hood Trauma Questionnaire (CTQ). CTQ is a 28-item
inventory that provides brief, reliable and valid screening
for histories of abuse and neglect. The CTQ inquires
about five types of maltreatment – emotional, physical,
and sexual abuse, and emotional and physical neglect –
with five items representing each type. Participants re-
spond to a series of statements about childhood events,
which are endorsed on a 5-point frequency scale (0 =
“never true”, 4 = “very often true”). Item scores are then
summed to produce scores that quantify the severity of
maltreatment in each area and that can be compared to
clinical data. Cut-off scores for detecting likely cases of
abuse and neglect are also provided. The CTQ was vali-
dated with data from over 2,000 respondents, including
both clinical and non referred groups [33]. Second, expos-
ure to DVA from intimate partner and other family mem-
bers will be measured using the Composite Abuse Scale
(CAS). The CAS is a widely used self-report of behaviors
that women describe as abusive by their partners [34]. It is
an easily administered measure that provides standardized
sub scale scores on four dimensions of DVA. It consists of
30 items presented in a six point format requiring respon-
dents to answer “never”, “only once”, “several times”,“monthly”, “weekly” or “daily” in a twelve month period.
The Severe Combined Abuse sub scale has 8 items that
represent severe physical abuse items, all sexual abuse
items, and physical isolation aspects of emotional abuse.
The Emotional Abuse subscale has 11 items that include
verbal, psychological, dominance and social isolation abuse
items. The Physical Abuse subscale has 7 of the less severe
physical abuse items and the Harassment subscale has 4
items that are about actual harassment. CAS is scored by
summating the frequency scores of the 30 items. The 0–5
for each item thus gives a possible score for each sub scale.
Cut-off scores to exclude women labeled abused incor-
rectly are provided. The CAS can give not only prevalence
figures, but also associations with other physical and emo-
tional co-morbidities. It has been used in specialized do-
mestic violence agencies, general practice, antenatal clinics,
emergency departments, and drug and alcohol clinics. The
CAS has demonstrated good acceptability and reliability,
with some evidence of criterion and external validity. To
measure DVA duration an item is added to the CAS asking
participants the length (“one occasion”, “up to 6 months”,
“up to 1 year”, “up to 3 years”, “up to 5 years”, and “more
than 5 years”) of abusive relationship.
Levels of stress and mental health of the participants will
be evaluated using five psychological instruments for
detecting the most common mental disorders alongside
with standardized questionnaire on use of alcohol and
drugs. First, the Generalized Anxiety Disorder Scale
(GAD-7) will be used to screen on probable cases of
generalized anxiety disorder and to assess symptom se-
verity. The GAD-7 is based on the most prominent
diagnostic features of the DSM-IV diagnostic criteria
for generalized anxiety disorder and has excellent reli-
ability, as well as criterion, construct, factorial, and pro-
cedural validity. The 7 items assess the frequency of
core symptoms of generalized anxiety disorder within
the past two weeks. Items are rated on a 4-point fre-
quency scale (0 = “not at all”, 3 = “nearly every day”)
with a total score ranging from 0 to 21. A score up to 4
indicates the absence of generalized anxiety disorder,
scores of 5–9 represent mild, scores of 10–14 represent
moderate and scores of 15 and higher represent severe
anxiety symptoms levels [35].
Second, Patient Health Questionnaire Depression Scale
(PHQ-9) will be used to diagnose major depression and as-
sess symptom severity. The PHQ-9 is based on the DSM-
IV diagnostic criteria for major depressive disorder and has
excellent reliability, as well as criterion, construct, factorial
and procedural validity. The 9 items assess the frequency
of depressive symptoms within the past two weeks. Items
are scored on a 4-point frequency scale from 0 = “not at
all” to 3 – “nearly every day” with a total score ranging
from 0 to 27. A cut-off point of >9 is recommended for the
screening of any depressive disorder. A score up to 4
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sent mild, scores of 10–14 represent moderate and scores
of 15 and higher represent severe depression [35,36].
Third, PTSD will be diagnosed using the PTSD Symp-
tom Scale: Self-Reported version (PSS-SR). The PSS-SR is
a 17-item measure that assesses the 17 DSM-IV symptoms
of PTSD. The severity over the last two weeks of each
item on the PSS-SR is rated using a 4-point scale (0 = “not
at all”, 4 = “every day”). The total score is calculated as the
sum of severity ratings for the 17 items. The total score >
13 indicates on likelihood of PTSD. The PSS-SR has satis-
factory internal consistency, high test-retest reliability, and
good concurrent validity [37].
Fourth, the Sheehan Disability Scale (SDS) will be used to
assess functional impairment in three inter-related do-
mains; work/school, social and family life. The participant
rates the extent to which work/school, social life and home
life or family responsibilities are impaired by her symptoms
on a 10-point visual analog scale. Score 5 or greater on any
of the three scales is associated with significant functional
impairment. The SDS has high sensitivity and good specifi-
city for patients with most frequent mental disorders [38].
Fifth, the Perceived Stress Scale (PSS) will be used for
measuring the perception of stress [39]. This widely used
10-item psychological instrument with good internal reli-
ability and moderate construct validity measures the
degree to which situations in one’s life are appraised as
stressful over the past month. It assesses the amount of
stress in one’s life rather than response to a specific stress
and had been used in studies of both mental and physical
health. The questions in the PSS ask about feelings and
thoughts during the last month. In each case, respondents
are asked how often they felt a certain way. Answers are
rated on a 5-point frequency scale (0 = “never”, 4 = “very
often”). PSS scores are obtained by reversing responses to
the four positively stated items and then summing across
all scale items. Scores can range from 0 to 40, with higher
scores indicating greater stress.
Finally, use of alcohol and drugs will be measured by
asking questions about quantity and frequency of sub-
stance use.
Physical health of the participants will be evaluated by
body mass index (BMI) and a standardized questionnaire.
To calculate BMI the researcher will follow standard clin-
ical protocol on taking standing height and weight. Height
will be measured to the nearest 1 mm (KaWe person-
check, Germany), weight to the nearest 0.1 kg (Seca 803
Digital Personal Scale, Germany). Physical health prob-
lems will be measured using a modification of the Miller
Abuse Physical Symptom and Injury Scale (MAPSAIS).
This self-reported scale lists 9 injuries and 44 symptoms
and illnesses related to DVA and asks if the woman was
hospitalized, visited emergency department or undertaken
surgery in the past 12 months. The scale was designedspecifically for measuring long-term health consequences
of DVA and demonstrated good content validity and test-
retest reliability [40].
Upon completion of questionnaire and anthropometry
study participants will be given a saliva sample collection
kit that includes a saliva collection device (Salivette tubes)
with cotton pledget, an illustrated instruction sheet written
in plain language explaining the procedure and providing
helpful hints (such as putting the tube next to the bed for
morning sample), a saliva collection diary in which partici-
pants can record experiences on the day of sample collec-
tion and a prepaid packaging addressed to the accredited
laboratory compliant with current postal regulations. The
participants will be asked to collect three saliva samples as
soon as possible after questionnaire survey:
1. Sample 1 “bedtime” – right before getting into bed.
2. Sample 2 “awakening” – next morning as soon as the
woman wakes up and is ready to get up for the day.
3. Sample 3 “post-awakening” – 30 minutes after taking
awakening sample.
Saliva will be collected by either passive drooling into
the tube or by chewing (for 2 minutes) the cotton
pledget provided with each tube. Participants must have
waited at least 30 minutes after smoking, consuming any
food or drink or teeth brushing before collecting the sal-
iva sample. Tubes will be labeled with patient identifier
and returned to the laboratory by post or via collection
by the researcher. Upon arrival to the laboratory tubes
with saliva will be centrifuged to remove the upper saliva
layer for subsequent measurement of cortisol. The pri-
mary tube including the cotton pledget with individual
cells will be then discarded in routine clinical waste. The
upper saliva layer will be frozen until analysis. The saliva
samples will be analyzed in the Department of Clinical
Biochemistry at the Bristol Royal Infirmary using Ultra
performance liquid chromatography – tandem mass spec-
trometry (UPLC-MSMS). The analysis also simultaneously
measures cortisone a metabolite of cortisol as an add-
itional measure of circulating cortisol [41,42].
To collect data on known covariates that have been re-
lated to diurnal cortisol secretion participants will complete
saliva collection diary [22]. Data collected on the day of sal-
iva sampling include: schedule (whether weekend vs. week-
day), time of awakening, lifestyle (smoking, alcohol use,
caffeine, exercise/activity level, perceived stress and negative
mood, recent meal, medications) and menstrual timing.
Statistical analysis
For the sample size calculation we used findings from simi-
lar studies in comparable populations [24,43,44]. Thus, the
number of participants required to detect a standardized
difference in cortisol levels of 0.5 between abused women
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score for statistical significance of 0.05 is 128 (64 per
group). Assuming 40% drop out rate before the study ends,
around 213 eligible subjects would have to be approached.
Assuming 60% response rate we will have to approach ap-
proximately 355 women, so 213 would consent to join the
study, and of these 128 would be expected to complete the
study.
Data will be coded and entered into research database
during data collection by the two researchers responsible
for recruitment. Stata software will be used for statistical
analysis. All data will be checked for expected ranges,
presence of outliers and abnormal values.
Sample will be analyzed by comparison of participant ex-
posed to DVA and participants without DVA exposure on
the basis of cortisol and mental health state data. Primary
study outcome will be reported as diurnal cortisol variation,
the degree of decline in cortisol across the day. Secondary
study outcomes include CAR, size of post-awakening surge
in cortisol that occurs in 30 minutes after awakening and
mean salivary cortisol concentration across the day. As an
additional measure of tissue cortisol the three saliva sam-
ples, awakening, post awakening, and bedtime, will also be
assayed for cortisone.
Following descriptive statistics for all the cortisol and
mental health outcomes, relationship between them will
be investigated using appropriate linear (and, for binary
outcomes, logistic) regression models. Using the CAS and
CTQ data, these techniques will also be used to investigate
the extent to which cortisol measures act as potential me-
diator between the type, duration and cessation of abuse
and mental health condition for this group of women.
Missing data from women who dropped out of the study
will be handled first by comparing their baseline variables
with those who completed the study, and secondly using
imputation techniques [45].
Discussion
The current study: (1) evaluates levels of stress, mental
health, and stress biomarker salivary cortisol for cur-
rently and recently abused women and non-abused
controls, across three time periods over 6 months; (2)
explores whether there are altered diurnal patterns of
cortisol secretion within this sample; and (3) identifies
socio-demographic, abuse and mental health predictors
of diurnal cortisol parameters. The study protocol and
participant documentation have been amended based
on guidance from our research advisory group (five
former SURVIVE users) and the pilot study. This study
is methodologically strong compared to very few neu-
roendocrinological studies previously conducted in
abused women. Firstly we use three-point saliva sam-
pling protocol across three time periods over 6 months
which enables us to obtain the key diurnal cortisolparameters prospectively – the diurnal cortisol slope,
the size of awakening response, and the average cortisol
exposure across the day. Secondly we shall collect data
on a number covariates related to diurnal cortisol se-
cretion in order to control neuroendocrine variables for
potential confounding. Thirdly UPLC-MSMS will be
used to measure salivary cortisol. UPLC-MSMS is a su-
perior technique to traditional immunoassay steroid
methods, with improved sensitivity and specificity
which is able to measure both salivary cortisol and cor-
tisone (cortisol metabolite) in the samples simultan-
eously. Fourthly to measure stress, mental health and
abuse we use international validated questionnaires. Fi-
nally our targeted sample size is larger than those
reported in earlier studies in women exposed to DVA
which allows performance of subgroup analysis strati-
fied by mental health status, and characteristics of
DVA.
This study should add significantly to our understanding
of the physiological mechanisms of DVA and explain
causal pathway between abuse and mental health conse-
quences in female survivors. It will improve understanding
of neuroendocrine markers associated with abuse and
mental health status, potentially leading to studies of prog-
nosis and more targeted management of women who have
experienced DVA and its sequelae. Ultimately it might be
possible to better target intervention for women experien-
cing DVA with and without specific mental health seque-
lae in relation to activity of HPA axis. The current study
represents a step on this direction.
Additional files
Additional file 1: Diurnal cortisol activity in women exposed to
childhood abuse (CHA) and DVA. PDF table summarizing
methodological information about publishes studies on HPA axis activity
in association with exposure to violence and abuse.
Additional file 2: Study plan and measurements. PDF table
summarizing CEASE study plan and measurements.
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